cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2023-38-2-64-71cardiotomsk-1788Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВторичная организующаяся пневмония после перенесенной новой коронавирусной инфекции (обзор литературы)Secondary organizing pneumonia after coronavirus disease (literature review)https://orcid.org/0000-0001-6867-5694ГофманЛ. С.GofmanL. S.

Гофман Людмила Сергеевна - врач-пульмонолог

650066, Российская Федерация, Кемерово, пр. Октябрьский, 22 

Liudmila S. Gofman - Pulmonologist

 22, Oktyabrsky str., Kemerovo, 650066, Russian Federation 

shelly.shell538@gmail.comhttps://orcid.org/0000-0002-2708-4940ШендриковВ. П.ShendrikovV. P.

Шендриков Валерий Павлович - студент

125047, Российская Федерация, Москва, Миусская пл., 9 

 Valery P. Shendrikov - Student

 9, Miusskaya Square, Moscow, 125047, Russian Federation 

valery.shendrikoff@gmail.comhttps://orcid.org/0000-0003-1828-012XМурлатоваЕ. Ю.MurlatovaE. Y.

Мурлатова Елизавета Юрьевна - специалист по клиническим исследованиям

121205, Российская Федерация, Москва, Большой бульвар, 42, стр. 1 

 Elizaveta Y. Murlatova - Clinical Trials Specialist

 42(1), Bolshoi Blvd., Moscow, 143026, Russian Federation 

e.murlatova@pharmenterprises.ruhttps://orcid.org/0000-0002-3023-6239БаздыревЕ. Д.BazdyrevE. D.

Баздырев Евгений Дмитриевич - д-р мед. наук, заведующий лабораторией эпидемиологии сердечно-сосудистых заболеваний

650002, Российская Федерация, Кемерово, Сосновый бульвар, 6 

Evgeny D. Bazdyrev - Dr. Sci. (Med.), Head of the Laboratory of Epidemiology of Cardiovascular Diseases

 6, Sosnovy Blvd., Kemerovo, 650002, Russian Federation 

edb624@mail.ruКузбасская областная клиническая больница имени С.В. БеляеваРоссияKuzbass Regional Clinical Hospital named after S.V. BelyaevRussian FederationРоссийский химико-технологический университет имени Д.И. МенделееваРоссияD.I. Mendeleev Russian University of Chemical TechnologyRussian FederationФарминтерпрайсезРоссияPharmenterprises LLCRussian FederationНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation2023050720233826471Copyright © Гофман Л.С., Шендриков В.П., Мурлатова Е.Ю., Баздырев Е.Д., 20232023Гофман Л.С., Шендриков В.П., Мурлатова Е.Ю., Баздырев Е.Д.Gofman L.S., Shendrikov V.P., Murlatova E.Y., Bazdyrev E.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1788

Новая коронавирусная инфекция (COVID-19) помимо угрожающего жизни острого течения способна приводить к развитию симптомов, сохраняющихся длительное время. Клиническая, радиологическая и гистопатологическая картина посткоронавирусной пневмонии имеет общие признаки со вторичной организующейся пневмонией (ВОП). Считается, что данный вариант пневмонии служит одним из вариантов осложнений во время болезни, что не только коррелирует с тяжестью заболевания, но и приводит к более высоким показателям смертности пациентов. Необходимо отметить, что рентгенологические симптомы пневмонии наблюдаются даже у выздоровевших лиц примерно в 67% случаев. Несмотря на то, что у 25% лиц заболевание разрешается самостоятельно, а у большинства других легко поддается лечению, в 5–8% случаев может развиться фиброз, сопровождающийся симптомами дыхательной недостаточности. Специфического метода лечения ВОП на фоне новой коронавирусной инфекции в настоящее время не существует, к терапии первой линии относят применение глюкокортикостероидов (ГКС). Несмотря на эффективность ГКС, курс лечения составляет в среднем более полугода, при этом высока вероятность рецидива при прекращении терапии. Для определения оптимальных дозировок и длительности ГКС в терапии ВОП после перенесенного COVID-19 зарегистрированы клинические исследования, но единого мнения по данному вопросу нет, он остается открытым. В данном обзоре представлена информация об организующейся пневмонии, а также ВОП на фоне перенесенной новой коронавирусной инфекции, ее рентгенологической картине и вариантах лечения в рамках проводимых клинических исследований.

New coronavirus disease (COVID-19) is a life-threatening infection that can lead to the development of persisting symptoms. Clinical, radiological and histopathological characteristics of post-coronavirus pneumonia are similar to secondary organizing pneumonia (SOP). This type of pneumonia is considered to be a complication of COVID-19, which correlates with the severity of the disease and increases patient mortality rates.It should be noted that radiological signs of pneumonia are can be observed in recovered individuals in 67% of cases. Moreover, fibrosis, complicated by symptoms of respiratory failure, may develop in 5-8% of the cases despite the fact that SOP resolves independently in 25% of individuals, and, in most cases, can be easily treated.Currently there are no methods of treating SOP induced by COVID-19; the first-line therapy involves the use of glucocorticosteroids (GCs). Despite the effectiveness of GCs, the treatment lasts for more than six months, and the disease has a high probability of relapse upon treatment discontinuation. Clinical trials have been registered to determine the optimal treatment duration and dosages of GCs in SOP treatment after COVID-19, however, the lack of consensus remains, keeping this issue open. This review provides data regarding organizing pneumonia, SOP induced by COVID-19, its radiological signs and treatment options within the framework of ongoing clinical trials.

новая коронавирусная инфекцияCOVID-19постковидный синдроминтерстициальная пневмонияорганизующаяся пневмониявторичная организующаяся пневмонияфиброз легкихnew coronavirus diseaseCOVID-19рost-COVID syndromeinterstitial pneumoniaorganizing pneumoniasecondary organizing pneumoniapulmonary fibrosisИсследование выполнено в рамках Комплексной научно-технической программы полного инновационного цикла «Разработка и внедрение комплекса технологий в области разведки и добычи твердых полезных ископаемых, обеспечения промышленной безопасности, биоремедиации, создания новых продуктов глубокой переработки из угольного сырья при последовательном снижении экологической нагрузки на окружающую среду и рисков для жизни населения» (утв. Распоряжением Правительства РФ от 11 мая 2022 г. № 1144-р, Соглашение № 075-15-2022-1202 от 30 сентября 2022 г.).The study was carried out within the framework of the Comprehensive Scientific and Technical Program of the Full Innovation Cycle entitled “Development and implementation of technologies in the field of exploration and extraction of solid minerals, industrial safety, bioremediation, obtaining new products of deep processing from raw coal with a consistent reduction in the environmental burden and environmental impact on the life of the population” (approved by Order of the Russian Federation Government No. 1144-r dated May 11, 2022, the Agreement No. 075-15-2022-1202 dated September 30, 2022).ReferencesБаздырев Е.Д. Коронавирусная инфекция – актуальная проблема XXI века. Комплексные проблемы сердечно-сосудистых заболеваний. 2020;9(2):6–16. DOI: 10.17802/2306-1278-2020-9-2-6-16.Bazdyrev E.D. Coronavirus disease: a global problem of the 21st century. Complex Issues of Cardiovascular Diseases. 2020;9(2):6–16. (In Russ.). DOI: 10.17802/2306-1278-2020-9-2-6-16.Wu X., Liu X., Zhou Y., Yu H., Li R., Zhan Q. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir. Med. 2021;9(7):747–754. DOI: 10.1016/S2213-2600(21)00174-0.Wu X., Liu X., Zhou Y., Yu H., Li R., Zhan Q. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir. Med. 2021;9(7):747–754. DOI: 10.1016/S2213-2600(21)00174-0.Raoufi M., Kahkooei S., Haseli S., Robatjazi F., Bahri J., Khalili N. Organizing pneumonia-like pattern in COVID-19. Advances in Respiratory Medicine. 2021;89(6):565–569. DOI: 10.5603/ARM.a2021.0081.Raoufi M., Kahkooei S., Haseli S., Robatjazi F., Bahri J., Khalili N. Organizing pneumonia-like pattern in COVID-19. Advances in Respiratory Medicine. 2021;89(6):565–569. DOI: 10.5603/ARM.a2021.0081.Wang Y., Jin C., Wu C.C., Zhao H., Liang T., Liu Z. et al. Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings. PLoS One. 2020;15(11):e0240347. DOI: 10.1371/journal.pone.0240347.Wang Y., Jin C., Wu C.C., Zhao H., Liang T., Liu Z. et al. Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings. PLoS One. 2020;15(11):e0240347. DOI: 10.1371/journal.pone.0240347.Horii H., Kamada K., Nakakubo S., Yamashita Y., Nakamura J., Nasuhara Y. et al. Rapidly progressive organizing pneumonia associated with COVID-19. Respir. Med. Case Rep. 2020;31:101295. DOI: 10.1016/j.rmcr.2020.101295.Horii H., Kamada K., Nakakubo S., Yamashita Y., Nakamura J., Nasuhara Y. et al. Rapidly progressive organizing pneumonia associated with COVID-19. Respir. Med. Case Rep. 2020;31:101295. DOI: 10.1016/j.rmcr.2020.101295.Bradley B., Branley H.M., Egan J.J., Greaves M.S., Hansell D.M., Harrison N.K. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(S5):v1–58. DOI: 10.1136/thx.2008.101691.Bradley B., Branley H.M., Egan J.J., Greaves M.S., Hansell D.M., Harrison N.K. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(S5):v1–58. DOI: 10.1136/thx.2008.101691.Kligerman S.J., Franks T.J., Galvin J.R. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics. 2013;33(7):1951–1975. DOI: 10.1148/rg.337130057.Kligerman S.J., Franks T.J., Galvin J.R. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics. 2013;33(7):1951–1975. DOI: 10.1148/rg.337130057.Pathak V., Kuhn J.M., Durham C., Funkhouser W.K., Henke D.C. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. Ann. Am. Thorac. Soc. 2014;11(1):87–91. DOI: 10.1513/AnnalsATS.201308-261CR.Pathak V., Kuhn J.M., Durham C., Funkhouser W.K., Henke D.C. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. Ann. Am. Thorac. Soc. 2014;11(1):87–91. DOI: 10.1513/AnnalsATS.201308-261CR.Cai M., Bonella F., Dai H., Sarria R., Guzman J., Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013;218(6):930–937. DOI: 10.1016/j.imbio.2012.10.014.Cai M., Bonella F., Dai H., Sarria R., Guzman J., Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013;218(6):930–937. DOI: 10.1016/j.imbio.2012.10.014.Poletti V., Cazzato S., Minicuci N., Zompatori M., Burzi M., Schiattone M.L. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur. Respir. J. 1996;9(12):2513–2516. DOI: 10.1183/09031936.96.09122513.Poletti V., Cazzato S., Minicuci N., Zompatori M., Burzi M., Schiattone M.L. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur. Respir. J. 1996;9(12):2513–2516. DOI: 10.1183/09031936.96.09122513.Lee W.L., Downey G.P. Neutrophil activation and acute lung injury. Curr. Opin. Crit. Care. 2001;7(1):1–7. DOI: 10.1097/00075198-200102000-00001.Lee W.L., Downey G.P. Neutrophil activation and acute lung injury. Curr. Opin. Crit. Care. 2001;7(1):1–7. DOI: 10.1097/00075198-200102000-00001.Ma Y., Zhang Y., Zhu L. Role of neutrophils in acute viral infection. Immun. Inflamm. Dis. 2021;9(4):1186–1196. DOI: 10.1002/iid3.500.Ma Y., Zhang Y., Zhu L. Role of neutrophils in acute viral infection. Immun. Inflamm. Dis. 2021;9(4):1186–1196. DOI: 10.1002/iid3.500.Radzikowska E., Roży A., Jaguś P., Wiatr E., Gawryluk D., Chorostowska-Wynimko J. et al. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. Adv. Exp. Med. Biol. 2016;911:77–85. DOI: 10.1007/5584_2016_223.Radzikowska E., Roży A., Jaguś P., Wiatr E., Gawryluk D., Chorostowska-Wynimko J. et al. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. Adv. Exp. Med. Biol. 2016;911:77–85. DOI: 10.1007/5584_2016_223.Baha A., Yıldırım F., Köktürk N., Galata Z., Akyürek N., Demirci N.Y. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiological and laboratory findings, treatment, and prognosis in 56 cases. Turk Thorac. J. 2018;19(4):201–208. DOI: 10.5152/TurkThoracJ.2018.18008.Baha A., Yıldırım F., Köktürk N., Galata Z., Akyürek N., Demirci N.Y. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiological and laboratory findings, treatment, and prognosis in 56 cases. Turk Thorac. J. 2018;19(4):201–208. DOI: 10.5152/TurkThoracJ.2018.18008.Gudmundsson G., Sveinsson O., Isaksson H.J., Jonsson S., Frodadottir H., Aspelund T. Epidemiology of organising pneumonia in Iceland. Thorax. 2006;61(9):805–808. DOI: 10.1136/thx.2006.059469.Gudmundsson G., Sveinsson O., Isaksson H.J., Jonsson S., Frodadottir H., Aspelund T. Epidemiology of organising pneumonia in Iceland. Thorax. 2006;61(9):805–808. DOI: 10.1136/thx.2006.059469.Allen J.N., Wewers M.D. HIV-associated bronchiolitis obliterans organizing pneumonia. Chest. 1989;96(1):197–198. DOI: 10.1378/chest.96.1.197.Allen J.N., Wewers M.D. HIV-associated bronchiolitis obliterans organizing pneumonia. Chest. 1989;96(1):197–198. DOI: 10.1378/chest.96.1.197.Nuñez-Conde A., Marquez-Algaba E., Falcó V., Almirante B., Burgos J. Organizing pneumonia secondary to influenza infection: Two case reports and a literature review. Enferm. Infecc. Microbiol. Clin. (Engl. Ed.). 2020;38(3):123–126. (In Span.). DOI: 10.1016/j.eimc.2019.04.006.Nuñez-Conde A., Marquez-Algaba E., Falcó V., Almirante B., Burgos J. Organizing pneumonia secondary to influenza infection: Two case reports and a literature review. Enferm. Infecc. Microbiol. Clin. (Engl. Ed.). 2020;38(3):123–126. (In Span.). DOI: 10.1016/j.eimc.2019.04.006.Messina M., Scichilone N., Guddo F., Bellia V. Rapidly progressive organising pneumonia associated with cytomegalovirus infection in a patient with psoriasis. Monaldi Arch. Chest Dis. 2007;67(3):165–168. DOI: 10.4081/monaldi.2007.489.Messina M., Scichilone N., Guddo F., Bellia V. Rapidly progressive organising pneumonia associated with cytomegalovirus infection in a patient with psoriasis. Monaldi Arch. Chest Dis. 2007;67(3):165–168. DOI: 10.4081/monaldi.2007.489.Myall K.J., Mukherjee B., Castanheira A.M., Lam J.L., Benedetti G., Mak S.M. et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann. Am. Thorac. Soc. 2021;18(5):799–806. DOI: 10.1513/AnnalsATS.202008-1002OC.Myall K.J., Mukherjee B., Castanheira A.M., Lam J.L., Benedetti G., Mak S.M. et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann. Am. Thorac. Soc. 2021;18(5):799–806. DOI: 10.1513/AnnalsATS.202008-1002OC.Drakopanagiotakis F., Paschalaki K., Abu-Hijleh M., Aswad B., Karagianidis N., Kastanakis E. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. Chest. 2011;139(4):893–900. DOI: 10.1378/chest.10-0883.Drakopanagiotakis F., Paschalaki K., Abu-Hijleh M., Aswad B., Karagianidis N., Kastanakis E. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. Chest. 2011;139(4):893–900. DOI: 10.1378/chest.10-0883.Choi K.J., Yoo E.H., Kim K.C., Kim E.J. Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia. BMC Pulm. Med. 2021;21(1):336. DOI: 10.1186/s12890-021-01707-z.Choi K.J., Yoo E.H., Kim K.C., Kim E.J. Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia. BMC Pulm. Med. 2021;21(1):336. DOI: 10.1186/s12890-021-01707-z.Chandra D., Maini R., Hershberger D.M. Cryptogenic Organizing Pneumonia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.Chandra D., Maini R., Hershberger D.M. Cryptogenic Organizing Pneumonia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.Greenberg-Wolff I., Konen E., Ben Dov I., Simansky D., Perelman M., Rozenman J. Cryptogenic organizing pneumonia: variety of radiologic findings. Isr. Med. Assoc. J. 2005;7(9):568–570.Greenberg-Wolff I., Konen E., Ben Dov I., Simansky D., Perelman M., Rozenman J. Cryptogenic organizing pneumonia: variety of radiologic findings. Isr. Med. Assoc. J. 2005;7(9):568–570.Demedts M., Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur. Respir. J. 2002;19(5):794–796. DOI: 10.1183/09031936.02.00492002.Demedts M., Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur. Respir. J. 2002;19(5):794–796. DOI: 10.1183/09031936.02.00492002.Wong K.T., Antonio G.E., Hui D.S., Ho C., Chan P.N., Ng W.H. et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004;28(6):790–795. DOI: 10.1097/00004728-200411000-00010.Wong K.T., Antonio G.E., Hui D.S., Ho C., Chan P.N., Ng W.H. et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004;28(6):790–795. DOI: 10.1097/00004728-200411000-00010.Nishino M., Mathai S.K., Schoenfeld D., Digumarthy S.R., Kradin R.L. Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. Hum. Pathol. 2014;45(2):342–351. DOI: 10.1016/j.humpath.2013.09.010.Nishino M., Mathai S.K., Schoenfeld D., Digumarthy S.R., Kradin R.L. Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. Hum. Pathol. 2014;45(2):342–351. DOI: 10.1016/j.humpath.2013.09.010.Onishi Y., Kawamura T., Higashino T., Mimura R., Tsukamoto H., Sasaki S. Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS One. 2021;16(4):e0249300. DOI: 10.1371/journal.pone.0249300.Onishi Y., Kawamura T., Higashino T., Mimura R., Tsukamoto H., Sasaki S. Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS One. 2021;16(4):e0249300. DOI: 10.1371/journal.pone.0249300.Kobayashi T., Kitaichi M., Tachibana K., Kishimoto Y., Inoue Y., Kagawa T. et al. A Cryptogenic Case of Fulminant Fibrosing Organizing Pneumonia. Intern. Med. 2017;56(10):1185–1191. DOI: 10.2169/internalmedicine.56.7371.Kobayashi T., Kitaichi M., Tachibana K., Kishimoto Y., Inoue Y., Kagawa T. et al. A Cryptogenic Case of Fulminant Fibrosing Organizing Pneumonia. Intern. Med. 2017;56(10):1185–1191. DOI: 10.2169/internalmedicine.56.7371.Kim M., Cha S.I., Seo H., Shin K.M., Lim J.K., Kim H. et al. Predictors of Relapse in Patients with Organizing Pneumonia. Tuberc. Respir. Dis. (Seoul). 2015;78(3):190–195. DOI: 10.4046/trd.2015.78.3.190.Kim M., Cha S.I., Seo H., Shin K.M., Lim J.K., Kim H. et al. Predictors of Relapse in Patients with Organizing Pneumonia. Tuberc. Respir. Dis. (Seoul). 2015;78(3):190–195. DOI: 10.4046/trd.2015.78.3.190.Ailing L., Ning X., Tao Q., Aijun L. Successful treatment of suspected organizing pneumonia in a patient without typical imaging and pathological characteristic: A case report. Respir. Med. Case Rep. 2017;22:246–250. DOI: 10.1016/j.rmcr.2017.09.007.Ailing L., Ning X., Tao Q., Aijun L. Successful treatment of suspected organizing pneumonia in a patient without typical imaging and pathological characteristic: A case report. Respir. Med. Case Rep. 2017;22:246–250. DOI: 10.1016/j.rmcr.2017.09.007.Barroso E., Hernandez L., Gil J., Garcia R., Aranda I., Romero S. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration. 2007;74(6):624–631. DOI: 10.1159/000103240.Barroso E., Hernandez L., Gil J., Garcia R., Aranda I., Romero S. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration. 2007;74(6):624–631. DOI: 10.1159/000103240.American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165(2):277–304. DOI: 10.1164/ajrccm.165.2.ats01.American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165(2):277–304. DOI: 10.1164/ajrccm.165.2.ats01.Ding Q.L., Lv D., Wang B.J., Zhang Q.L., Yu Y.M., Sun S.F. et al. Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review. Exp. Ther. Med. 2015;9(3):829–834. DOI: 10.3892/etm.2015.2183.Ding Q.L., Lv D., Wang B.J., Zhang Q.L., Yu Y.M., Sun S.F. et al. Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review. Exp. Ther. Med. 2015;9(3):829–834. DOI: 10.3892/etm.2015.2183.Radzikowska E., Wiatr E., Langfort R., Bestry I., Skoczylas A., Szczepulska-Wójcik E. et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. PLoS One. 2017;12(9):e0184739. DOI: 10.1371/journal.pone.0184739.Radzikowska E., Wiatr E., Langfort R., Bestry I., Skoczylas A., Szczepulska-Wójcik E. et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. PLoS One. 2017;12(9):e0184739. DOI: 10.1371/journal.pone.0184739.Cano E.J., Fonseca Fuentes X., Corsini Campioli C., O ҆Horo J.C., Abu Saleh O., Odeyemi Y. et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019–1040. DOI: 10.1016/j.chest.2020.10.054.Cano E.J., Fonseca Fuentes X., Corsini Campioli C., O ҆Horo J.C., Abu Saleh O., Odeyemi Y. et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019–1040. DOI: 10.1016/j.chest.2020.10.054.Epler G.R. Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options? Expert. Rev. Respir. Med. 2011;5(3):353–361. DOI: 10.1586/ers.11.19.Epler G.R. Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options? Expert. Rev. Respir. Med. 2011;5(3):353–361. DOI: 10.1586/ers.11.19.Lee J., Cha S.I., Park T.I., Park J.Y., Jung T.H., Kim C.H. Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern. Med. 2011;50(5):475–479. DOI: 10.2169/internalmedicine.50.4237.Lee J., Cha S.I., Park T.I., Park J.Y., Jung T.H., Kim C.H. Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern. Med. 2011;50(5):475–479. DOI: 10.2169/internalmedicine.50.4237.Koinuma D., Miki M., Ebina M., Tahara M., Hagiwara K., Kondo T. et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern. Med. 2002;41(1):26–29. DOI: 10.2169/internalmedicine.41.26.Koinuma D., Miki M., Ebina M., Tahara M., Hagiwara K., Kondo T. et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern. Med. 2002;41(1):26–29. DOI: 10.2169/internalmedicine.41.26.Kory P., Kanne J.P. SARS-CoV-2 organising pneumonia: “Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?” BMJ Open Respir. Res. 2020;7(1):e000724. DOI: 10.1136/bmjresp-2020-000724.Kory P., Kanne J.P. SARS-CoV-2 organising pneumonia: “Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?” BMJ Open Respir. Res. 2020;7(1):e000724. DOI: 10.1136/bmjresp-2020-000724.Vadász I., Husain-Syed F., Dorfmüller P., Roller F.C., Tello K., Hecker M. et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76(2):201–204. DOI: 10.1136/thoraxjnl-2020-216088.Vadász I., Husain-Syed F., Dorfmüller P., Roller F.C., Tello K., Hecker M. et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76(2):201–204. DOI: 10.1136/thoraxjnl-2020-216088.Kanne J.P., Little B.P., Chung J.H., Elicker B.M., Ketai L.H. Essentials for Radiologists on COVID-19: An Update-Radiology Scientific Expert Panel. Radiology. 2020;296(2):E113–E114. DOI: 10.1148/radiol.2020200527.Kanne J.P., Little B.P., Chung J.H., Elicker B.M., Ketai L.H. Essentials for Radiologists on COVID-19: An Update-Radiology Scientific Expert Panel. Radiology. 2020;296(2):E113–E114. DOI: 10.1148/radiol.2020200527.Fu F., Lou J., Xi D., Bai Y., Ma G., Zhao B. et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur. Radiol. 2020;30(10):5489–5498. DOI: 10.1007/s00330-020-06920-8.Fu F., Lou J., Xi D., Bai Y., Ma G., Zhao B. et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur. Radiol. 2020;30(10):5489–5498. DOI: 10.1007/s00330-020-06920-8.Rocha A.S., Meireles M., Vilaça H., Guimarães T.C., Martins M.D., Santos L.R. et al. Outcomes of Covid-19 organizing pneumonia in critically ill patients. J. Infect. 2021;83(4):496–522. DOI: 10.1016/j.jinf.2021.06.025.Rocha A.S., Meireles M., Vilaça H., Guimarães T.C., Martins M.D., Santos L.R. et al. Outcomes of Covid-19 organizing pneumonia in critically ill patients. J. Infect. 2021;83(4):496–522. DOI: 10.1016/j.jinf.2021.06.025.Antonio G.E., Wong K.T., Hui D.S., Wu A., Lee N., Yuen E.H. et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228(3):810–815. DOI: 10.1148/radiol.2283030726.Antonio G.E., Wong K.T., Hui D.S., Wu A., Lee N., Yuen E.H. et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228(3):810–815. DOI: 10.1148/radiol.2283030726.Cheung O.Y., Chan J.W., Ng C.K., Koo C.K. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology. 2004;45(2):119–124. DOI: 10.1111/j.1365-2559.2004.01926.x.Cheung O.Y., Chan J.W., Ng C.K., Koo C.K. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology. 2004;45(2):119–124. DOI: 10.1111/j.1365-2559.2004.01926.x.Kim I., Lee J.E., Kim K.H., Lee S., Lee K., Mok J.H. Successful treatment of suspected organizing pneumonia in a patient with Middle East respiratory syndrome coronavirus infection: a case report. J. Thorac. Dis. 2016;8(10):E1190–E1194. DOI: 10.21037/jtd.2016.09.26.Kim I., Lee J.E., Kim K.H., Lee S., Lee K., Mok J.H. Successful treatment of suspected organizing pneumonia in a patient with Middle East respiratory syndrome coronavirus infection: a case report. J. Thorac. Dis. 2016;8(10):E1190–E1194. DOI: 10.21037/jtd.2016.09.26.Elsoukkary S.S., Mostyka M., Dillard A., Berman D.R., Ma L.X., Chadburn A. et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56–68. DOI: 10.1159/000511325.Elsoukkary S.S., Mostyka M., Dillard A., Berman D.R., Ma L.X., Chadburn A. et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56–68. DOI: 10.1159/000511325.Borczuk A.C. Pulmonary pathology of COVID-19: a review of autopsy studies. Curr. Opin. Pulm. Med. 2021;27(3):184–192. DOI: 10.1097/MCP.0000000000000761.Borczuk A.C. Pulmonary pathology of COVID-19: a review of autopsy studies. Curr. Opin. Pulm. Med. 2021;27(3):184–192. DOI: 10.1097/MCP.0000000000000761.Copin M.C., Parmentier E., Duburcq T., Poissy J., Mathieu D. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46(6):1124–1126. DOI: 10.1007/s00134-020-06057-8.Copin M.C., Parmentier E., Duburcq T., Poissy J., Mathieu D. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46(6):1124–1126. DOI: 10.1007/s00134-020-06057-8.Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. DOI: 10.1016/j.carpath.2020.107233.Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. DOI: 10.1016/j.carpath.2020.107233.Liu H., Li J., Chen M., Su J. Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: A case report. Medicine (Baltimore). 2019;98(34):e16839. DOI: 10.1097/MD.0000000000016839.Liu H., Li J., Chen M., Su J. Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: A case report. Medicine (Baltimore). 2019;98(34):e16839. DOI: 10.1097/MD.0000000000016839.Roden A.C., Bois M.C., Johnson T.F., Aubry M.C., Alexander M.P., Hagen C.E. et al. The Spectrum of Histopathologic Findings in Lungs of Patients With Fatal Coronavirus Disease 2019 (COVID-19) Infection. Arch. Pathol. Lab. Med. 2021;145(1):11–21. DOI: 10.5858/arpa.2020-0491-SA.Roden A.C., Bois M.C., Johnson T.F., Aubry M.C., Alexander M.P., Hagen C.E. et al. The Spectrum of Histopathologic Findings in Lungs of Patients With Fatal Coronavirus Disease 2019 (COVID-19) Infection. Arch. Pathol. Lab. Med. 2021;145(1):11–21. DOI: 10.5858/arpa.2020-0491-SA.Barbeta E., Benegas M., Sánchez M., Motos A., Ferrer M., Ceccato A. et al. Risk Factors and Clinical Impact of Fibrotic-Like Changes and the Organizing Pneumonia Pattern in Patients With COVID-19- and NonCOVID-19-Induced Acute Respiratory Distress Syndrome. Arch. Bronconeumol. 2022;58(2):183–187. DOI: 10.1016/j.arbres.2021.05.023.Barbeta E., Benegas M., Sánchez M., Motos A., Ferrer M., Ceccato A. et al. Risk Factors and Clinical Impact of Fibrotic-Like Changes and the Organizing Pneumonia Pattern in Patients With COVID-19- and NonCOVID-19-Induced Acute Respiratory Distress Syndrome. Arch. Bronconeumol. 2022;58(2):183–187. DOI: 10.1016/j.arbres.2021.05.023.Bae I.-G., Hong K.-W., Yang J.W., Moon K.l., Kim J.D., Ju S. et al. Persistent pneumonic consolidations due to secondary organizing pneumonia in a patient recovering from COVID19 pneumonia: A case report. Preprint (Version 1) available at Research Square; 2020. DOI: 10.21203/rs.3.rs-37580/v1.Bae I.-G., Hong K.-W., Yang J.W., Moon K.l., Kim J.D., Ju S. et al. Persistent pneumonic consolidations due to secondary organizing pneumonia in a patient recovering from COVID19 pneumonia: A case report. Preprint (Version 1) available at Research Square; 2020. DOI: 10.21203/rs.3.rs-37580/v1.Dhooria S. Comparison of the efficacy and safety of two corticosteroid regimens in the treatment of diffuse lung disease after coronavirus disease 2019 (COVID-19) pneumonia. ClinicalTrials.gov; 2022. URL: https://clinicaltrials.gov/ct2/show/NCT04657484 (27.01.2023).Dhooria S. Comparison of the efficacy and safety of two corticosteroid regimens in the treatment of diffuse lung disease after coronavirus disease 2019 (COVID-19) pneumonia. ClinicalTrials.gov; 2022. URL: https://clinicaltrials.gov/ct2/show/NCT04657484 (27.01.2023).Goel N., Goyal N., Nagaraja R., Kumar R. Systemic corticosteroids for management of “long-COVID”: an evaluation after 3 months of treatment. Monaldi Arch. Chest. Dis. 2021;92(2). DOI: 10.4081/monaldi.2021.1981.Goel N., Goyal N., Nagaraja R., Kumar R. Systemic corticosteroids for management of “long-COVID”: an evaluation after 3 months of treatment. Monaldi Arch. Chest. Dis. 2021;92(2). DOI: 10.4081/monaldi.2021.1981.Ayub I.I. Clarithromycin in Post Covid 19 parenchymal organizing pneumonia. Clinical Trials Registry-India; 2020. URL: https://covid-19.cochrane.org/studies/crs-16896926 (13.12.2022).Ayub I.I. Clarithromycin in Post Covid 19 parenchymal organizing pneumonia. Clinical Trials Registry-India; 2020. URL: https://covid-19.cochrane.org/studies/crs-16896926 (13.12.2022).Tan H.X., Lim J.L., shih Khor I., Kew Y.Ch., Yik W.F., Chan Y.M. et al. P16-60: Post COVID-19 organizing pneumonia treated with mycophenolate mofetil. Respirology. 2021;26(S3):473–474. DOI: 10.1111/resp.14150_969.Tan H.X., Lim J.L., shih Khor I., Kew Y.Ch., Yik W.F., Chan Y.M. et al. P16-60: Post COVID-19 organizing pneumonia treated with mycophenolate mofetil. Respirology. 2021;26(S3):473–474. DOI: 10.1111/resp.14150_969.Sugino K., Ono H., Haraguchi S., Igarashi S., Hebisawa A., Tsuboi E. Post-coronavirus disease 2019 organizing pneumonia confirmed pathologically by video-assisted thoracoscopic surgery. Respirol. Case Rep. 2021;9(12):e0871. DOI: 10.1002/rcr2.871.Sugino K., Ono H., Haraguchi S., Igarashi S., Hebisawa A., Tsuboi E. Post-coronavirus disease 2019 organizing pneumonia confirmed pathologically by video-assisted thoracoscopic surgery. Respirol. Case Rep. 2021;9(12):e0871. DOI: 10.1002/rcr2.871.

The authors declare that there are no conflicts of interest present.